G
lioblastoma is the most common and the most lethal malignant brain tumor (1) . Even for patients receiving aggressive treatment, the median survival is 12 to 15 months (2) . The tumors evolve rapidly as they acquire new mutations; the resultant increase in intratumor genomic heterogeneity leads to the development of drug resistance, which limits the long-term efficacy of therapies (3, 4) . Two large-scale efforts aimed at characterizing the genomic alterations in human glioblastoma are The Cancer Genome Atlas (TCGA), which is a catalog of multi-omics data, including genomics, transcriptomics, DNA methylomics, proteomics, etc. (5, 6) , and REMBRANDT (Repository for Molecular Brain Neoplasia Data), which also includes multiple data domains (7) . These efforts helped to clarify the role of genomic alterations in the pathogenesis of glioblastoma but were not designed to address intratumor heterogeneity. Subsequent studies addressed heterogeneity spatially within bulk tumor or at the single-cell level (4, (8) (9) (10) (11) (12) . Nonetheless, we still lack a systematic understanding of the tumor's molecular heterogeneity as it relates to anatomical heterogeneity. By "anatomical heterogeneity," we mean the variable combination of the classical histological features of glioblastoma, such as tumor infiltration, endothelial cell proliferation, and necrosis. Here, we describe the Ivy Glioblastoma Atlas (http://glioblastoma. alleninstitute.org/), a comprehensive molecular pathology map of glioblastoma in which we have assigned key genomic alterations and gene expression profiles to the tumor's anatomic features. The atlas will facilitate accurate deconvolution of anatomic features in new samples of glioblastoma, providing unique information for the comprehensive diagnostic characterization of the tumor's heterogeneity.
To create the atlas, we surveyed the tumor's anatomic features by in situ hybridization (ISH), analyzed these features' transcriptomes by laser microdissection (LMD) and RNA sequencing (RNA-seq), and validated the feature-specific gene expression enrichment of newly identified markers by ISH (Fig. 1) . We created a clinical and genomic database (http://ivygap.org/) for the 41-patient cohort (table S1) whose tumors (n = 42) were evaluated to create the atlas. We describe gene sets whose expression is enriched in the anatomic features, measurements of intraand intertumor heterogeneity, and a molecular subtype classification of transcriptomic samples from our atlas and from TCGA. Together, these two online resources constitute the Ivy Glioblastoma Atlas Project (Ivy GAP).
To identify gene sets with enriched expression in each anatomic feature ( fig. S1 ), we used LMD to isolate RNA from the leading edge (LE), infiltrating tumor (IT), cellular tumor (CT), pseudopalisading cells around necrosis (PAN), and microvascular proliferation (MVP). In total, we isolated 122 samples from three different blocks per tumor in 8 to 10 tumors. In consultation with a neuropathologist, we manually drew outlines (LMD guidelines) for each of the anatomic features on images of histologically stained tissue sections. Three additional neuropathologists independently validated the LMD guidelines, and the results showed excellent concordance (table S2) . Differential gene expression analysis revealed a total of 3627 genes that had enriched expression in LE, CT, PAN, and MVP samples ( Fig. 2A and table S3 ). Multidimensional scaling demonstrated that samples from these four features were largely distinct, whereas IT appeared to fall on a continuum between LE and CT (Fig. 2B) . Gene Ontology enrichment analysis of gene sets with enriched expression in anatomic features (Fig. 2C ) confirmed and extended previous reports (13, 14) . In general, samples from the same anatomic feature, whether derived from the same or different tumors, were more similar to each other than to samples from other anatomic features of the same tumor (Fig. 2D) . Within a given anatomic feature, intertumor heterogeneity exceeded intratumor heterogeneity ( fig. S2) .
We selected 31 genes with enriched expression in anatomic features for further analysis by ISH, and found that 27 showed at least partial agreement and 22 showed good agreement between RNA-seq and ISH assessments of enrichment in PAN, CT, or MVP ( Fig. 2 , E to I, and table S4). Assessing enrichment of gene expression by ISH required that we calculate the overlap between the expression pattern and our machine learning (ML) annotations for each anatomic feature, which we validated using (i) ML-determined rates of accuracy and precision (table S5); (ii) an interneuropathologist test to establish agreement on definitions of anatomic features ( fig. S1 and tables S6 and S7); and (iii) neuropathology concordance analyses (tables S8 to S11).
To characterize intratumor genetic heterogeneity across anatomic features, we assessed RNA-seq-derived copy number changes in the features and compared them to the DNA-level copy number variations (CNVs) (12) from the corresponding bulk tumor ( fig. S3 and table S12 ). The CT and PAN samples consistently showed gene expression changes corresponding to the CNVs, whereas LE samples did not, as LE samples by definition consist largely of non-neoplastic cells and hence would not harbor the CNVs. On the other hand, MVP samples showed some gene expression changes corresponding to the CNVs, indicating a mixture of tumor and nonneoplastic cells. To evaluate the distribution of somatic mutations targeting key glioblastoma genes within the different anatomic features of this tumor, we used RNA-seq to call singlenucleotide variants (SNVs) in eight genes (TP53, PTEN, EGFR, ATRX, IDH1, NF1, PIK3R1, PIK3CA) known to harbor recurrent and functionally important mutations in glioblastoma across anatomic features for tumors where there was at least one sample available from each of the LE, CT, PAN, and MVP features ( fig. S4 and table S13). We detected somatically mutated alleles in RNA from CT, PAN, and MVP samples, whereas we found only the wild-type variants in LE samples ( fig. S4A ). The ratio of mutant to wildtype expression was least for MVP relative to CT and PAN samples (fig. S4B) . Some of the SNVs occurring across anatomic features were corroborated by ISH data (table S1). Together, the copy number and mutation analyses indicated that LE samples largely consist of nonneoplastic cells, CT and PAN samples largely consist of tumor cells, and MVP samples contain a mixture of tumor and non-neoplastic cells. The observed intratumor heterogeneity in copy number and mutation profiles is consistent with previous studies (8, 9) . Only three tumors from our 41-patient cohort harbored the Arg 132 → His mutation in isocitrate dehydrogenase 1 (IDH1) (table S1); thus, there was insufficient statistical power for analysis of this mutation by anatomic feature. We did not identify any mutation associated with a particular anatomic feature that predicted overall survival better than the promoter methylation status of the MGMT gene in the bulk tumor ( fig. S5, A and B) (15) .
Finally, we developed an admixture model using a 293-gene signature matrix (table S14) PAN, and MVP) and classified the 122 anatomic feature RNA-seq samples on the basis of histology, admixture (table S14), molecular subtype (6), and cell type gene expression signature (table S15) enrichment (fig. S6, A to D, and table  S16 ). Several genes exhibited differential expression across known molecular subtypes of glioblastoma within each anatomic feature ( fig.  S7, A to C) . Enrichment of the cell type gene expression signatures in the anatomic features was consistent with Gene Ontology enrichment analyses (Fig. 2C) . The correlation between the anatomic feature gene sets and molecular subtypes (table S16) is broadly consistent with results of previous studies (8, 9) . When we applied our admixture model to 167 RNA-seq samples of the TCGA data, we observed similar patterns ( fig. S8 , A to C, and related to the pathogenesis, diagnosis, and treatment of glioblastoma. We note that investigators are already leveraging this resource (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) . In one preclinical study, Miller et al. (22) used the atlas to prioritize potential druggable targets based on relationships to tumor microenvironment signatures. In another preclinical study, Yu et al. (31) used the Ivy GAP data set to identify anatomic regions of glioblastoma that are enriched in tumor-initiating cells. On the basis of this information, they delivered an experimental drug to these tumor regions as a way to maximize its therapeutic effect.
